Diagnosis and management of iron deficiency anemia in inflammatory bowel disease

Am J Manag Care. 2021 Jul;27(11 Suppl):S211-S218. doi: 10.37765/ajmc.2021.88714.

Nicole Bohm 1


Author information

  • 1Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, Medical University of South Carolina, Charleston, SC. Email: bohm@musc.edu.


Inflammatory bowel disease (IBD) is associated with extraintestinal manifestations in more than one-quarter of patients. Anemia is one of the most common concerns. Patients with IBD and comorbid iron deficiency anemia (IDA) are at risk for hospitalization and surgery, and IDA impacts health-related quality of life. IDA in IBD is often underdiagnosed and undertreated. Prompt treatment has the potential to improve patient quality of life and clinical outcomes. Although the treatment goals for IDA in IBD are well-defined, selecting a treatment is not as straightforward. Traditional oral iron replacement therapies are generally only recommended in patients with mild anemia who do not have active inflammatory disease. Novel oral iron formulations may circumvent some of the limitations associated with traditional oral products.



© Copyright 2013-2022 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.